/Methods For Treatment Of Cd20-positive Proliferative Disorder With Mosunetuzumab And Polatuzumab Vedotin
Abstract
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
Full Text
What is claimed is:
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
Timeline
Filed
05/21/2026Published
09/10/2026Granted
Not AvailableIPC Codes(3)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61P 35/00:Antineoplastic agents